21:57 , Feb 14, 2019 |  BC Innovations  |  Emerging Company Profile

Indalo: Integral to fibrosis

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Antegrin, Cascadia deal

Antegrin and Cascadia merged to form Indalo Therapeutics Inc. (St. Louis, Mo.). The newco is developing treatments for fibrotic diseases affecting the kidney, liver, and lung using Antegrin’s portfolio of small molecule integrin antagonists, including...
07:00 , May 3, 2004 |  BioCentury  |  Finance

Ebb & Flow

Genentech got a 12% bump on Monday when partner OSI (OSIP) reported that its Tarceva small molecule EGFr inhibitor significantly increased survival in a Phase III trial in recurrent non-small cell lung cancer (NSCLC). The...